Fusion Pharmaceuticals Inc

NASDAQ FUSN

Data sourced from

and

Daily

Download Data

Fusion Pharmaceuticals Inc Price to Book Ratio (P/B) on June 03, 2024: 7.58

Fusion Pharmaceuticals Inc Price to Book Ratio (P/B) is 7.58 on June 03, 2024, a 434.11% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Fusion Pharmaceuticals Inc 52-week high Price to Book Ratio (P/B) is 8.18 on April 30, 2024, which is 7.97% above the current Price to Book Ratio (P/B).
Fusion Pharmaceuticals Inc 52-week low Price to Book Ratio (P/B) is 0.77 on August 04, 2023, which is -89.83% below the current Price to Book Ratio (P/B).
Fusion Pharmaceuticals Inc average Price to Book Ratio (P/B) for the last 52 weeks is 3.25.

NASDAQ: FUSN

Fusion Pharmaceuticals Inc

CEO	Dr. John F. Valliant Ph.D.
IPO Date	March 14, 2016
Location	Canada
Headquarters	270 Longwood Road South, Hamilton, ON, Canada, L8P 0A6
Employees	101
Sector	Healthcare
Industry	Biotechnology

Description

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.

Key trends